Clinical trials: Neutrophil Lymphocyte Ratio
Bladder Cancer
Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710
The purpose of this study is to perform a secondary analysis of SWOG 8710 to assess NLRs value as a biomarker. Specifically, the investigators test two hypotheses: 1) that baseline NLR is correlated with overall survival after…
- Trial name
- NCT02756637
- Where
- United States
- Volunteers
- 634 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer, Metastatic Breast Cancer
Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.
The impact of the inflammatory microenvironment in predicting the benefit of a CDK4/6 inhibitor in the treatment of locally advanced or first line metastatic breast cancer has not yet been studied.
- Trial name
- PEPSI (NCT05303129)
- Testing
- Blood sampling
- Where
- 2 sites in France
- Volunteers
- 165 people
- Sponsor
- Centre Francois Baclesse
Myocardial Infarction, Death
Relation Between NLR and IMR in STEMI Patients
The neutrophil-to-lymphocyte ratio (NLR) has been proven to be reliable inflammatory marker for atherosclerotic process and predictor for clinical outcomes in patients with various cardiovascular diseases.
- Trial name
- NCT02828137
- Volunteers
- 123 people
- Sponsor
- Inha University Hospital